SOURCE: Amazon Biotech, Inc

November 14, 2006 06:30 ET

Amazon Biotech Inc. Announces Union Bless Herbal Products' Application for Amendment to Approved Import Drug License to Include Amazon Biotech as Approved Supplier

Privately Held Philippines Company to Import Amazon Biotech's Primary Drug Candidate for HIV/AIDS

NEW YORK, NY -- (MARKET WIRE) -- November 14, 2006 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D) today announced that its distributor in the Philippines, Union Bless Herbal Products, is applying for an amendment to its current approved drug import license, in order to include Amazon as an approved supplier.

BFAD, the Philippines Bureau of Food and Drugs, is the governmental body responsible for granting import licenses for foods and drugs into the Philippines. Union Bless Herbal Products has been granted such a license for natural drug therapies, and now is adding Amazon Biotech to that license for the importation of AMZ0026, Amazon Biotech's therapeutic herbal composition and primary drug candidate for HIV/AIDS. Although it does not imply approval for distribution, receiving this import license is the first step to conduct clinical trials in that country. AMZ0026 is currently under Investigational New Drug (IND) status by the US FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: To be included on the corporate e-mail list, send a request to

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 -- This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information